Merck, Bionomics team up to develop chronic pain drug

Bionomics and Merck & Co. agreed to collaborate in the discovery and development of novel small molecule candidates for treatment of neuropathic pain and other forms of chronic pain using the latter's ionX drug discovery technology and MultiCore chemistry. The deal grants Merck an option for an exclusive license for one compound. Bionomics could get as much as $172 million in option exercise fees and milestone payments plus sales royalties.

View Full Article in:

Genetic Engineering & Biotechnology News · Wall Street Journal (tiered subscription model), The

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Market Access Manager Electrophysiology HEOR (AEP) - 15000003NZ
Abbott
Menlo Park, CA